Migraine

Zavegepant could become the first intranasal drug that targets CGRP in migraine sufferers to gain FDA approval.

Atogepant is an oral calcitonin gene-related peptide receptor antagonist approved in 2021 for patients with episodic migraines.

Research into how perivascular spaces contribute to migraine could help better understand the complexities of how these headaches occur.

Investigational migraine drug produces significant effects on both freedom-from-pain and MBS-free endpoints at 3 hours post administration and at additional efficacy measurement timepoints of 4, 6, 12, 24 and 48 hours.

Updated prescribing guidelines issued in 2014 and 2016 may explain lower use of opioids by 11.7% among patients with chronic, nonsurgical pain.

A session presenter at the ASCP 2022 Annual Meeting explained how patients’ mismanagement of medications for headaches can lead to rebound headaches.

Problems such as sleep deprivation, excessive sleeping, or inability to sleep regularly may be an important factor in the transition from episodic to chronic migraines.

Case studies highlight recent developments and trends in pharmacologic treatments for migraine.

New treatments for chronic migraine have been increasing, with robust evidence for eptinezumab, erenumab, fremanezumab, galcanezumab, and onabotulinumtoxin A.

Nerivio (Theranica) remote electrical neuromodulation device found to offer similar pain relief as standard care medications as an alternative for patients with chronic migraine.

Teva Pharmaceutical Industries announced that fremanezumab can successfully reduce 2 common migraine comorbid symptoms—anxiety and depression.

Surveys show that 70% of migraine sufferers are not satisfied with their current acute treatment regimen.

Patients with chronic migraines and higher frequencies of pain experienced the lowest vitamin B12 levels compared with patients with less frequent or no headache symptoms.

Though around 42% of medical students in study experience headaches, many of these causing significant functional disability, most choose to self-manage symptoms with sleep and medication.

Analysis is based on functional magnetic resonance imaging to provide insight into the effective connectivity.

Investigators aimed to determine how individuals with and without concomitant NSP differ in characteristics and in their perception of treatment responses to analgesics.

Study will analyze whether cognitive behavioral therapy telehealth can lower headache days and disability as effectively as cognitive behavioral therapy plus a preventive medication for migraine.

Survey finds that 91% of health care providers and 67% of people with migraines feel that individuals who are able to successfully manage stress and mental health conditions can also better manage the symptoms of migraine.

Researchers highlight how a lack of access to medications used to treat multiple sclerosis, migraines, and epilepsy, but not proven safe for pregnancy, threatens child-bearing aged women who live with these conditions.

The submission is based on 2 pivotal phase 3 studies evaluating the drug in adult patients with chronic and episodic migraines.

A study demonstrated the role of the serotonin 1B receptor in appetite and showed that triptan, a commonly prescribed migraine medicine, may be repurposed for appetite suppression and obesity.

Triptans are contraindicated in patients with ischemic heart disease, cerebrovascular disease, uncontrolled hypertension, and peripheral artery disease.

Patients with refractory chronic migraine experience short- and medium-term pain relief and minimal adverse drug effects from lidocaine infusions.

Migraine Be KoooL is intended to provide relief from headaches, fever, muscle aches, sprains, and over-exertion.

Investigators studied the efficacy and safety of eptinezumab-jjmr in the 100 mg and 300 mg intravenous infusion dosages in individuals with 2 to 4 documented unsuccessful prior preventive treatment failures for migraine in the past 10 years.

Submission is based on phase 2 study results evaluating atogepant in adults who met the primary endpoint of a statistically significant reduction from the baseline compared with a placebo.

Migraines can have a high cost for the health care system overall, with an estimated $1 billion dollars or more spent in indirect and direct costs.

Options include calcitonin gene-related peptide antagonists, ergotamine, hormone therapy, lasmiditan, and triptans.

Real-world data show fremanezumab-vfrm (Ajovy) injection plus gepants combination effective in patients with difficult-to-treat migraine.